symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
AUPH,7.84,1.231247,2135451,1124428480,0,4.07-12.43,-0.08,Aurinia Pharmaceuticals Inc.,USD,0001600620,CA05156V1022,05156V102,NASDAQ Global Market,NASDAQ,Biotechnology,https://www.auriniapharma.com,"Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.",Mr. Peter S. Greenleaf M.B.A.,Healthcare,CA,300,12507084272,4464 Markham Street,Victoria,BC,V8Z 7X8,2.77259,6.59741,https://financialmodelingprep.com/image-stock/AUPH.png,2014-09-03,False,False,True,False,False
